U.S. Stock Market Midday Update: HCW Biologics' shareholder equity surged, and the stock price soared nearly 15%

U.S. Stock Market Midday Update HCW Biologics rose 14.94%. Based on recent key news: On December 31, HCW Biologics reported progress in compliance with Nasdaq, with an increase in shareholder equity. The company raised $3.8 million through warrant inducement, increased equity credit by $363,858, and added $5.4 million in shareholder equity through a settlement agreement. These measures enhanced the company's shareholder equity while awaiting formal confirmation of compliance from Nasdaq, driving the stock price up. On December 31, HCW Biologics released relevant documents through the EDGAR system, detailing the increase in shareholder equity. This move further boosted market confidence in the company's financial health, promoting an increase in stock price. The biotechnology industry has been volatile recently and requires attention. Stocks with High Trading Volume in the Industry Ironwood Pharmaceuticals rose 29.38%. Based on recent news: On January 2, Ironwood Pharmaceuticals announced that its 2026 revenue expectations exceeded Wall Street's expectations, with projected net sales of Linzess reaching between $1.125 billion and $1.175 billion, and total revenue between $450 million and $475 million, driving the stock price up. Source: Benzinga On January 2, Ironwood Pharmaceuticals announced that its adjusted EBITDA for 2026 is expected to exceed $300 million, a significant increase from last year, further boosting market confidence. Source: MarketWatch On January 2, Ironwood Pharmaceuticals' stock price rose over 30% in pre-market trading due to its 2026 revenue guidance exceeding market expectations. Source: Reuters The biotechnology industry has shown strong performance recently, with significant capital inflow. AbbVie rose 0.48%, with active trading. Based on recent key news: On December 31, AbbVie reached a strategic cooperation agreement with Zai Lab, obtaining exclusive development and commercialization rights for ZG006 outside of Greater China. This move is seen as an important layout for AbbVie in the field of innovative drugs, driving the stock price up. Source: Zhitong Finance On December 31, AbbVie acquired Cerevel's M4 receptor modulator Emraclidine. Although the Phase II clinical trial did not meet expectations, the company plans to explore its potential by adjusting dosages and expanding indications, demonstrating continued investment in innovative drugs and boosting market confidence. Source: Kechuangban Daily On January 1, analysts held an optimistic view on AbbVie's long-term trend, believing that the rise of its 200-day moving average indicates a bullish trend. Although the relative strength index is in a neutral zone, the overall technical outlook supports an increase in stock price. Source: Stockcharts.com The pharmaceutical industry is actively developing innovative drugs, with significant capital inflow Gilead Sciences fell 0.86%. Based on recent key news: On December 31, Gilead Sciences Chairman and CEO Daniel Patrick O'Day sold 10,000 shares of common stock for a transaction amount of $1,248,272. This sale may lead to a decline in market confidence in the company's leadership, thereby affecting the stock price. On December 31, Gilead Sciences announced an agreement with the U.S. government aimed at reducing drug costs. This initiative may impact the company's future profitability, leading to stock price fluctuations. On December 31, market analysis showed that Gilead Sciences had an annualized return exceeding the market by 1.5% over the past 15 years, but recent analyst ratings were a moderate buy, and it was not included in the top recommended stocks, which may affect investor confidence. Policy changes in the pharmaceutical industry impact stock price volatility. Stocks ranked among the top in industry market capitalization Amgen rose 0.38%. Based on recent news, On January 1, Amgen's stock price reached $328.43 per share, with a return of 17.6% over the past six months, outperforming the S&P 500 index by 6.3%. This growth is primarily attributed to the company's strong quarterly performance, driving the stock price up. On December 31, Amgen was listed as one of the best pharmaceutical stocks for 2026. Despite facing patent expiration risks, its strong financial performance and stable clinical progress supported the rise in stock price. On January 1, Amgen was one of the "dogs" of the Dow Jones, with a high dividend yield. It is expected that in the context of anticipated Federal Reserve interest rate cuts, investors may turn to high-dividend stocks for returns, further driving up the stock price. Expectations of Federal Reserve rate cuts impact stock market volatility